Back to search results
NCT06699810

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

Recruiting
PHASE4Ages 18+InterventionalBasic science
Emory University
~12 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:Continuous Glucose MonitoringInsulin

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quantify Changes in Blood Glucose
Measured over Up to 3 months
+1 more outcome measured

Conditions

Ketosis Prone Diabetes

Explore related trials

Ketosis-Prone DiabetesType 2 Diabetes Mellitus

Where it's being run

2 sites across 1 states
Georgia2

Study leadership

  • Priyathama Vellanki, MD, MS · PRINCIPAL_INVESTIGATOR · Emory University

Who to contact

Priyathama Vellanki, MD, MS
[email protected]
(404) 778-1687
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provide informed consent
Have a BMI ≥ 28 kg/m2
Be of African American ancestry
Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \> 250 mg/dl, a venous pH \< 7.30, a serum bicarbonate \< 18 mmol/l, and serum ketones (beta-hydroxy butyrate) \> 1.5 mmol/L.

Exclusion

Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes
Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism
Anemia (hemoglobin \< 12.5 g/dL for men, \<11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies
Pregnant
Diagnosis of diabetes \> 90 days before the presentation of DKA
Unable to give consent

What this trial measures

  • Quantify Changes in Blood GlucoseUp to 3 months

    The day-to-day changes in blood glucose in KPDM will be quantified using CGMs.

  • Development of Mathematical ModelsUp to 3 months

    The study team will adapt and develop mathematical models to describe the course of KPDM remission in each individual patient, i.e. the entire range of variation within the group of 12 participants.